Emmaus Life Sciences, Inc. Sustainability Profile
Emmaus Life Sciences, Inc., a leading biopharmaceutical company headquartered in the United States, is dedicated to developing innovative therapies for rare diseases. Founded in 2002, the company has made significant strides in the industry, particularly in the treatment of sickle cell disease. Emmaus is renowned for its flagship product, Endari, which is the first FDA-approved treatment specifically for patients aged five and older with this condition. The unique formulation of L-glutamine in Endari helps reduce the frequency of painful crises and hospitalisations, setting it apart in the market. With a strong commitment to research and development, Emmaus Life Sciences continues to expand its operational reach, aiming to improve the quality of life for patients globally. The company’s dedication to addressing unmet medical needs positions it as a notable player in the biopharmaceutical landscape.
DitchCarbon Score
How does Emmaus Life Sciences, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Emmaus Life Sciences, Inc.'s score of 23 is lower than 71% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Emmaus Life Sciences, Inc.'s reported carbon emissions
Emmaus Life Sciences, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, the company has not established any documented reduction targets or climate pledges, which suggests a lack of formal commitments to address carbon emissions at this time. In the context of the industry, many organisations are increasingly adopting science-based targets and sustainability initiatives to mitigate climate impact. However, without specific emissions data or commitments, Emmaus Life Sciences, Inc. appears to be at a nascent stage in its climate strategy. As the global focus on climate action intensifies, it may be beneficial for the company to consider setting measurable targets and engaging in initiatives that align with industry standards.
How Carbon Intensive is Emmaus Life Sciences, Inc.'s Industry?
How Carbon Intensive is Emmaus Life Sciences, Inc.'s Location?
Emmaus Life Sciences, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Emmaus Life Sciences, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
